Article
Impact of genotype-predicted CYP2D6 metabolism on clinical effects and tolerability of metoprolol in patients after myocardial infarction - a prospective observational study.
European journal of clinical pharmacology - 1 May 2020
Anstensrud Anne Kristine, Molden Espen, Haug Hans Jørgen, Qazi Rehman, Muriq Hysen, Fosshaug Linn E, Spigset Olav, Øie Erik
Abstract excerpt
PURPOSE: The β-1 adrenergic receptor blocker metoprolol is primarily metabolized by the polymorphic enzyme cytochrome P 450 2D6 (CYP2D6), an enzyme with substantial genetic heterogeneity. Our purpose was to investigate the impact of CYP2D6 metabolism on clinical effects and tolerability of metoprolol in patients after myocardial infarction (MI). METHODS: We included 136 patients with MI discharged on treatment...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.